WORLD HEALTH ORGANIZATION

A qualitative study in Beijing explores patient, pharmacist, and GP perspectives on outpatient participation in medication safety for NCDs, identifying themes like mutual trust, communication, medication knowledge, self-management, and decision-making attitudes. Challenges include poor patient knowledge, limited GP time, and low shared decision-making awareness. Strategies to enhance participation include more GPs, integrating pharmacists, better education, and judicious use of digital health tools.

WHO prequalifies MVA-BN vaccine for mpox, facilitating increased access to combat outbreaks. The vaccine, administered in two doses four weeks apart, has an estimated 82% effectiveness. WHO emphasizes the need for urgent scale-up in procurement and distribution to ensure equitable access, especially in Africa.

WHO approved MVA-BN mpox vaccine for first time, aiming to facilitate timely access for millions at risk in Africa. The vaccine, already approved in Europe and the US, can be administered in two doses with 82% effectiveness. WHO's prequalification aims to accelerate procurement and regulatory approval worldwide.

Vanderbilt University Medical Center joins ReVAMPP, a $100 million/year NIH program to develop vaccines and antibody therapies against viral threats, with a $13 million/year grant for bunyaviruses and picornaviruses research.

WHO announces MVA-BN vaccine as the first mpox vaccine to be added to its prequalification list, manufactured by Danish lab Bavarian Nordic A/S. This approval aims to facilitate timely access, reduce transmission, and help contain outbreaks. The vaccine is administered in two doses, 4 weeks apart, for individuals over 18 years old.

WHO approves first mpox vaccine, MVA-BN from Bavarian Nordic, to aid Africa's outbreak; vaccine prequalification aims to accelerate access and reduce transmission.

Genomics England leverages AWS and Amazon SageMaker to prepare digital pathology images for research and machine learning model development. The integration of whole slide images (WSI) with genomic data enhances cancer diagnosis and treatment, offering a multimodal 'pathogenomic' approach. This method combines genomic information with tissue architecture, improving classification tasks and potentially identifying new treatment targets. Genomics England collaborates with the National Pathology Imaging Cooperative (NPIC) to scan and transfer pathology slides, ensuring data quality and robustness for ML. AWS services like Amazon S3 and SageMaker facilitate data processing, de-identification, and accessibility for researchers.

Japan's Ministry of Health, Labor and Welfare approves KOSTAIVE®, the first self-amplifying mRNA COVID-19 vaccine for adults 18 and older, targeting the JN.1 lineage of Omicron subvariants. Meiji Seika Pharma, CSL's partner in Japan, will distribute the vaccine in time for the October COVID-19 vaccination campaign.